Citil Pharma

Citil Pharma is a biotechnology company developing next-generation in situ CAR-T and NK cell therapies for cancer and autoimmune disease. Its approach is designed to generate or program CAR immune cells in vivo using a combination of nanobody CAR constructs (nanoCAR), tumor-modulating circular RNAs branded as Tmode, and nanobody-targeted lipid nanoparticles. The company states that it is pursuing applications in hematologic malignancies, solid tumors, and autoimmune diseases. Based on publicly available information, Citil Pharma appears to be an early-stage platform biotech focused on cell therapy enabling technologies rather than a disclosed late-stage clinical pipeline.